Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes

Pharmacotherapy

Volumn 34, Issue 6, 2014, Pages 590-604

  Ganetsky, Valerie S ^a   Hadley, Diane E ^a   Thomas, Tyan F ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

acute coronary syndrome; anticoagulation; novel oral anticoagulant; oral anticoagulant; oral direct factor Xa inhibitor; oral direct thrombin inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DAREXABAN; EPTIFIBATIDE; HEPARIN; LETAXABAN; OTAMIXABAN; PEGNIVACOGIN; PLACEBO; RIVAROXABAN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; TREATMENT OUTCOME; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG COMBINATION; HEMORRHAGE; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION;

EID: 84902176240     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1375     Document Type: Review

References (47)

1. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73.
2. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 357: 1045-57.
5. Fox KAA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755-64.
6. Ardissino D, Merlini PA, Bauer KA, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003; 102: 2731-5.
7. Andreotti F, Testa L, Biondi-Zoccai GGL, Crea F,. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006; 27: 519-26.
8. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR,. Warfarin plus aspirin after myocardial infarction or the acute coronary syndromes: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-50.
9. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-74.
10. Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260-70.
11. Phillips KW, Ansell J,. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost 2010; 103: 34-9.
12. Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran) package insert. Ridgefield, CT; 2012.
13. Bristol-Meyers Squibb. Apixaban (Eliquis) package insert. Princeton, NJ; 2012.
14. Janssen Pharmaceuticals, Inc. Rivaroxaban (Xarelto) package insert. Titusville, NJ; 2011.
15. Ageno WA, Gallus AS, Wittkowsky AK, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e44S-88S.
16. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillations and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012; 59: 1413-25.
17. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.
18. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM trial. Lancet 2003; 362: 789-97.
19. Mega JL, Braunwald E, Wiviott S, et al. Rivaroxaban in patient with a recent acute coronary syndrome (ATLAS ACS 2-TIMI 51). N Engl J Med 2012; 366: 9-19.
20. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after an ST-elevation myocardial infarction: results from the ATLAS ACS 2-TIMI 51 trial. J Am Coll Cardiol 2013; 61: 853-9.
21. Rivaroxaban FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). May 2012. Available from http://www.fda.gov/ downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM304755.pdf. Accessed July 17, 2013.
22. FDA issues complete response letter for Xarelto (rivaroxaban) for the reduction of cardiovascular events in patients with acute coronary syndrome. PRNewswire, March 4, 2013. Available from http://www.prnewswire.com/news- releases/fda-issues-complete-response-letter-for-xarelto-rivaroxaban-for-the- reduction-of-cardiovascular-events-in-patients-with-acute-coronary-syndrome- 195162691.html. Accessed July 17, 2013.
23. FDA issues complete response letter for Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome [press release]. June 28, 2013. Available from http://www.prnewswire.com:news-releases: fda-issues-complete-response-letter-for-xarelto-rivaroxaban-to-reduce-the-risk- of-stent-thrombosis-in-patients-with-acute-coronary-syndrome-213480081.html. Accessed July 9, 2013.
24. Bayer Healthcare. Bayer's Xarelto approved in the EU for secondary prevention after an acute coronary syndrome [press release]. May 24, 2013. Available from http://press.healthcare.bayer.com/en/press/news-details-page.php/ 15050/2013-0292. Accessed June 23, 2013.
25. Steg G, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.
26. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009; 119: 2877-85.
27. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
28. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
29. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
30. Cohen M, Deepak L, Alexander J, et al. Randomized double-blind, dose ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention (the SEPIA-PCI trial). Circulation 2007; 115: 2642-51.
31. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patient with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomized, double-blind, active-controlled, phase 2 trial. Lancet 2009; 374: 787-95.
32. Steg PG, Mehta SR, Pollack CV,. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J 2012; 164: 818-24.
33. Citation for on-going trial of the TAO trial. Available from http://clinicaltrials.gov/show/NCT01076764. Accessed June 28, 2013.
34. Steg G, Mehta S, Jukema W,. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 322: 541-54.
35. Astellas Pharma Inc. News Release, September 2011. Available from http://www.astellas.com/en/corporate/news/pdf/110928-en.pdf. Accessed July 17, 2013.
36. Takeda Pharmaceutical Company Limited. TAK-442 press release. Available from http://www.takeda.com/news/2010/20101026-3802.html. Accessed July 17, 2013.
37. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, Phase II trial. Eur Heart J 2011; 32: 2781-9.
38. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013; 127: 634-40.
39. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490-7.
40. Povsic TJ, Wargin WA, Alexander JH, et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamics substudy. Eur Heart J 2011; 32: 2412-9.
41. Povsic TJ, Vavalle JP, Aberle LH, et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 2013; 34: 2481-9.
42. Komosci A, Vorobcsuk A, Kehl D, et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome. Arch Intern Med 2012; 172: 1537-45.
43. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patient taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet 2013; 381: 1107-15.
44. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62: 981-9.
45. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thromb Haemost 2011; 106: 571-84.
46. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.
47. Verheugt FWA, Clemmensen P, Mehran R, et al. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. Eur Heart J 2013; 34: 1621-9.